Medicus Pharma CEO awarded 125,000 share stock option at $1.8

Medicus Pharma Ltd. (MDCX) reported an equity award to its Chief Executive Officer and director, Raza Bokhari.

Rhea-AI Filing Summary

Medicus Pharma Ltd. (MDCX) reported an equity award to its Chief Executive Officer and director, Raza Bokhari. On December 16, 2025, he received a stock option covering 125,000 common shares with an exercise price of $1.8 per share and an expiration date of December 16, 2030. The option is scheduled to vest quarterly in four equal installments over one year, meaning the award becomes fully vested after that period if service conditions are met. Following the grant, 125,000 derivative securities are shown as beneficially owned with direct ownership.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Bokhari Raza

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	125,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 125,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medicus Pharma (MDCX) disclose in this Form 4?

Medicus Pharma disclosed that its Chief Executive Officer and director, Raza Bokhari, received a stock option grant for 125,000 common shares on December 16, 2025.

What is the exercise price and term of the Medicus Pharma (MDCX) stock option granted to the CEO?

The stock option granted to Raza Bokhari has an exercise price of $1.8 per share and an expiration date of December 16, 2030.

How does the Medicus Pharma (MDCX) CEO stock option vest?

The option granted to Raza Bokhari is scheduled to vest quarterly in four equal installments over one year, as described in the filing.

How many derivative securities does the Medicus Pharma (MDCX) CEO beneficially own after the reported transaction?

After the reported transaction, Raza Bokhari is shown as beneficially owning 125,000 derivative securities related to the stock option, held with direct ownership.

What roles does the reporting person hold at Medicus Pharma (MDCX)?

The reporting person, Raza Bokhari, is identified as both a Director and an Officer, serving as the company’s Chief Executive Officer.

Was the Medicus Pharma (MDCX) Form 4 filed by more than one reporting person?

No. The filing indicates it is a Form filed by one reporting person, specifically Raza Bokhari.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bokhari Raza

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.8	12/16/2025		A		125,000		(1)	12/16/2030	Common Shares	125,000	$0	125,000	D

Explanation of Responses:

1. The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.